Biotest Aktiengesellschaft

BATS-CHIXE:BIO3D Stock Report

Market Cap: €1.5b

Biotest Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Michael Ramroth

Chief executive officer

€2.7m

Total compensation

CEO salary percentage20.4%
CEO tenure19.3yrs
CEO ownershipn/a
Management average tenure1.4yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Ramroth's remuneration changed compared to Biotest's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-€47m

Dec 31 2022n/an/a

-€32m

Sep 30 2022n/an/a

-€69m

Jun 30 2022n/an/a

-€65m

Mar 31 2022n/an/a

-€54m

Dec 31 2021€3m€555k

-€63m

Sep 30 2021n/an/a

-€28m

Jun 30 2021n/an/a

-€33m

Mar 31 2021n/an/a

-€35m

Dec 31 2020€2m€462k

-€31m

Sep 30 2020n/an/a

-€34m

Jun 30 2020n/an/a

-€24m

Mar 31 2020n/an/a

-€15m

Dec 31 2019€1m€426k

-€5m

Sep 30 2019n/an/a

-€9m

Jun 30 2019n/an/a

-€3m

Mar 31 2019n/an/a

-€6m

Dec 31 2018€1m€355k

-€13m

Sep 30 2018n/an/a

€18m

Jun 30 2018n/an/a

€6m

Mar 31 2018n/an/a

€500k

Dec 31 2017€1m€355k

-€16m

Sep 30 2017n/an/a

-€48m

Jun 30 2017n/an/a

-€47m

Mar 31 2017n/an/a

-€29m

Dec 31 2016€1m€355k

€6m

Compensation vs Market: Michael's total compensation ($USD2.97M) is above average for companies of similar size in the UK market ($USD1.95M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Ramroth (61 yo)

19.3yrs

Tenure

€2,724,000

Compensation

Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Ramroth
Chairman of the Management Board & CEO19.3yrs€2.72mno data
Ainhoa Zubiaga
Member of Management Board & CFOless than a yearno datano data
Jorg Schuttrumpf
Chief Scientific Officer & Member of the Management Board1.4yrsno datano data
Peter Janssen
COO & Member of Management Boardless than a yearno datano data
Monika Buttkereit
Head of Investor Relationsno datano datano data
Christina Erb
Head of Corporate HR7.8yrsno datano data
Dirk Schuck
Member of Supervisory Board1.4yrsno datano data

1.4yrs

Average Tenure

50yo

Average Age

Experienced Management: BIO3D's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Dirk Schuck
Member of Supervisory Board1.1yrsno datano data
Uta Kemmerich-Keil
Member of Supervisory Board1.1yrsno datano data
Raimon Grifols Roura
Member of Supervisory Boardless than a yearno datano data
Bernhard R. Ehmer
Chairman of the Supervisory Board1.1yrs€598.00kno data
David Bell
Member of Supervisory Boardless than a yearno datano data
Jurgen Heilmann
Employee Representative Member of Supervisory Board11.8yrs€44.00kno data

1.1yrs

Average Tenure

59yo

Average Age

Experienced Board: BIO3D's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/26 08:00
End of Day Share Price 2023/03/29 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biotest Aktiengesellschaft is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BraunCommerzbank AG
Martin PossienkeGSN North America
Torben TeichlerHauck Aufhäuser Investment Banking